What are the latest medical insurance regulations for dasatinib?

As targeted therapy gradually matures in the field of leukemia, dasatinib, as one of the core drugs for the treatment of Philadelphia chromosome-positive leukemia, has been continuously updated in my country's medical insurance policy. According to the latest adjustment document of the National Medical Insurance Catalog, dasatinib fumarate tablets have been included in the scope of medical insurance reimbursement. The implementation of this policy has greatly reduced the financial burden on patients during long-term medication. Medical insurance coverage is not limited to adult patients, but also includes children over a certain age, especially patients who have poor tolerance to treatment or who have failed first-line treatment in the treatment of chronic phase Ph+ chronic myelogenous leukemia (CML) or Ph+ (ALL).

The current version reimbursed by medical insurance mainly includes domestically approved specifications, such as100mg*30 tablet packaging. In terms of reimbursement ratios, various regions have set different deductibles and reimbursement ratios based on their own medical insurance policies. Generally, first-tier cities have more comprehensive medical insurance coverage, and the patient out-of-pocket ratio is significantly lower. More importantly, some regions have also included it in outpatient special disease reimbursement projects, so that patients who do not need to be hospitalized can also enjoy a higher proportion of cost reductions, which is of great significance in the long-term management of chronic diseases.

It is worth mentioning that although medical insurance reimbursement has greatly reduced patients’ financial pressure, it does not mean that all brands and all specifications are eligible for reimbursement. The medical insurance catalog generally gives priority to covering original drugs or domestic generic drugs that have passed the consistency evaluation. When choosing a drug, patients should first check whether it is included in the local medical insurance reimbursement catalog. At the same time, some regions may require doctors to issue special diagnosis certificates, medical records, and special medical insurance applications before the reimbursement process for dasatinib can be officially started.

Reference materials:https://go.drugbank.com/drugs/DB01254